Noema Pharma Receives FDA Fast Track Designation for Basimglurant

BASEL, Switzerland, October 18, 2022– Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials